Calcium Channel Dysfunction In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Calcium (Ca²⁺) signaling is fundamental to neuronal function, controlling neurotransmitter release, gene transcription, synaptic plasticity, and cellular survival. Dysregulation of calcium homeostasis is a hallmark of neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). This pathway page explores the molecular mechanisms of calcium channel dysfunction and its contribution to neurodegeneration. [1]
Neurons maintain precise control over intracellular calcium concentrations through a sophisticated network of channels, pumps, buffers, and transporters. Disruption of this equilibrium leads to: [2]
| Channel Type | Gene | Primary Location | Function | [3]
|--------------|------|------------------|----------| [4]
| L-type (CaV1.x) | CACNA1A-D | Dendrites, cell body | Gene transcription, plasticity | [5]
| N-type (CaV2.2) | CACNA1B | Presynaptic terminals | Neurotransmitter release | [6]
| P/Q-type (CaV2.1) | CACNA1A | Presynaptic terminals | neurotransmitter release | [7]
| R-type (CaV2.3) | CACNA1E | Dendrites, terminals | Residual Ca²⁺ influx | [8]
| Channel Type | Gene | Primary Location | Function | [9]
|--------------|------|------------------|----------| [10]
| T-type (CaV3.x) | CACNA1G-I | Thalamic neurons | Pacemaking, burst firing | [11]
In AD, the endoplasmic reticulum (ER) calcium store becomes depleted due to: [12]
The depleted ER triggers store-operated calcium entry (SOCE) through plasma membrane channels (ORAI1, STIM1), leading to excessive Ca²⁺ influx. [13]
Dopaminergic neurons in the substantia nigra pars compacta (SNc) rely on L-type Ca²⁺ channels (CaV1.3) for autonomous pacemaking. This creates: [14]
| Drug/Compound | Target | Clinical Status | Notes |
|---|---|---|---|
| Isradipine | CaV1.2 | Phase 2/3 (AD) | Failed to meet primary endpoints |
| Nilvadipine | CaV1.2 | Phase 3 (AD) | Mixed results |
| Flunarizine | CaV2.2 | Approved (migraine) | Potential neuroprotective effects |
| Ziconotide | CaV2.1 | Approved (pain) | Too toxic for chronic use |
| Component | Gene | Function | Disease Relevance |
|---|---|---|---|
| CaV1.2 | CACNA1C | L-type, dendritic Ca²⁺ | AD risk gene |
| CaV1.3 | CACNA1D | L-type, pacemaking | PD vulnerability |
| CaV2.2 | CACNA1B | N-type, presynaptic | Therapeutic target |
| CaV2.1 | CACNA1A | P/Q-type, release | Ataxia, migraine |
| CaV3.1 | CACNA1G | T-type, thalamic | Epilepsy, AD |
| STIM1 | STIM1 | SOCE sensor | ER Ca²⁺ store depletion |
| ORAI1 | ORAI1 | SOCE channel | Store-operated influx |
| RyR1-3 | RYR1-3 | ER Ca²⁺ release | AD increased leak |
| SERCA2 | ATP2A2 | ER Ca²⁺ reuptake | AD decreased activity |
| NCX | SLC8A1-3 | Mitochondrial Ca²⁺ | Mitochondrial dysfunction |
The study of Calcium Channel Dysfunction In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
🟡 Moderate Confidence
| Dimension | Score |
|---|---|
| Supporting Studies | 15 references |
| Replication | 0% |
| Effect Sizes | 25% |
| Contradicting Evidence | 33% |
| Mechanistic Completeness | 50% |
Overall Confidence: 43%
Surmeier DJ, Schumacker PT, Guzman JD, et al. Calcium, mitochondria, and the pathophysiology of Parkinson's disease. Nat Rev Neurosci. 2017. ↩︎
Khachaturian ZS. Calcium hypothesis of Alzheimer's disease and brain aging. Neurobiol Aging. 1994. ↩︎
Stutzmann GE. Calcium dysregulation, IP₃ signaling, and Alzheimer's disease. Neuroscientist. 2007. ↩︎
Mattson MP. Calcium and neurodegeneration. Cell Calcium. 2004. ↩︎
Popugaeva E, Pchitskaya E, Bezprozvanny I. Dysregulation of neuronal calcium homeostasis in Alzheimer's disease - a therapeutic opportunity? Cell Calcium. Cell Calcium. 2018. ↩︎
Chan CS, Gertler TS, Surmeier DJ. Calcium homeostasis, selective vulnerability and Parkinson's disease. Trends Neurosci. 2009. ↩︎
Giacomello M, Barbiero L, Zotti G, et al. Ca²⁺ dysregulation in neurons from transgenic mice expressing mutant presenilin 1. Neurobiol Aging. 2005. ↩︎
Demuro A, Parker I. Cytotoxicity of intracellular Aβ42 aggregates involves Ca²⁺ release from endoplasmic reticulum stores. Cell Calcium. 2006. ↩︎
Berridge MJ. Calcium signalling and Alzheimer's disease. Neurochem Res. 2011. ↩︎
Palop JJ, Mucke L. Synaptic alterations in AD mouse models. Nat Neurosci. 2014. ↩︎
Zündorf G, Reiser G. Calcium dysregulation and its relationship to oxidative stress in neurodegenerative diseases. Antioxid Redox Signal. 2011. ↩︎
Marongiu R, Spencer B, Crews L, et al. Mutant alpha-synuclein causes calcium dysregulation in Parkinson's disease. J Neurosci. 2009. ↩︎
Ilari A, Giunta CF, Di Nardo AA, et al. Targeting calcium signaling in ALS. CNS Neurol Disord Drug Targets. 2020. ↩︎
Wang Y, Shi Y, Wei H. 'Calcium dysregulation in Alzheimer''s disease: from mechanisms to therapeutic strategies'. Int J Mol Sci. 2023. ↩︎